Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis. A 5-year longitudinal study

Journal of the Neurological Sciences

Volumn 282, Issue 1-2, 2009, Pages 112-119

  Horakova, Dana ^a   Dwyer, Michael G ^b   Havrdova, Eva ^a   Cox, Jennifer L ^b   Dolezal, Ondrej ^a   Bergsland, Niels ^b   Rimes, Brett ^b   Seidl, Zdeněk ^a   Vaneckova, Manuela ^a   Zivadinov, Robert ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Brain atrophy; Disability; Gray matter; MRI; Multiple sclerosis; Relapse rate; White matter

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; PREDNISONE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN THIRD VENTRICLE; CONTROLLED STUDY; DETERIORATION; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAY MATTER; GRAY MATTER ATROPHY; HUMAN; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; WHITE MATTER; WHITE MATTER ATROPHY;

ADULT; ATROPHY; AZATHIOPRINE; BRAIN; CEREBRAL VENTRICLES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBERS, MYELINATED; PREDNISONE; PROGNOSIS; RECURRENCE;

EID: 66149111820     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.12.005     Document Type: Article

References (54)

1. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 5 (1998) 278-285
2. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 4 (1996) 907-911
3. Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 6 3 (2006) 357-364
4. Zivadinov R., and Leist T.P. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 15 4_suppl (2005) 10S-21S
5. Bakshi R., Minagar A., Jaisani Z., and Wolinsky J.S. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2 2 (2005) 277-303
6. Miller D.H., Barkhof F., Frank J.A., Parker G.J., and Thompson A.J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125 Pt 8 (2002) 1676-1695
7. Fisniku L.K., Brex P.A., Altmann D.R., Miszkiel K.A., Benton C.E., Lanyon R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131 Pt 3 (2008) 808-817
8. Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67 6 (2006) 968-972
9. O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., Kendall B.E., Rudge P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 Pt 3 (1998) 495-503
10. Chard D.T., Griffin C.M., Parker G.J., Kapoor R., Thompson A.J., and Miller D.H. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125 Pt 2 (2002) 327-337
11. Sanfilipo M.P., Benedict R.H., Sharma J., Weinstock-Guttman B., and Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 26 4 (2005) 1068-1077
12. Sastre-Garriga J., Ingle G.T., Chard D.T., Ramio-Torrenta L., Miller D.H., and Thompson A.J. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 22 1 (2004) 353-359
13. Fisher E., Lee J.C., Nakamura K., and Rudick R.A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64 3 (2008) 255-265
14. Fisniku L.K., Chard D.T., Jackson J.S., Anderson V.M., Altmann D.R., Miszkiel K.A., et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 64 3 (2008) 247-254
15. Dalton C.M., Chard D.T., Davies G.R., Miszkiel K.A., Altmann D.R., Fernando K., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127 Pt 5 (2004) 1101-1107
16. Tiberio M., Chard D.T., Altmann D.R., Davies G., Griffin C.M., Rashid W., et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64 6 (2005) 1001-1007
17. Valsasina P., Benedetti B., Rovaris M., Sormani M.P., Comi G., and Filippi M. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 65 7 (2005) 1126-1128
18. Horakova D., Cox J.L., Havrdova E., Hussein S., Dolezal O., Cookfair D., et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 79 4 (2008) 407-414
19. Brex P.A., Jenkins R., Fox N.C., Crum W.R., O'Riordan J.I., Plant G.T., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54 8 (2000) 1689-1691
20. Dalton C.M., Miszkiel K.A., O'Connor P.W., Plant G.T., Rice G.P., and Miller D.H. Ventricular enlargement in MS: one-year change at various stages of disease. Neurology 66 5 (2006) 693-698
21. Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63(9):1301-06.
22. Havrdova E Z.R., Krasensky J., Dwyer M.G., Novakova I., Dolezal O., Ticha V., et al. Efficacy results from a randomised, double-blind, placebo-controlled study of intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 12 Suppl 1 (2006) P61, S11
23. Zivadinov R., Horakova D., Dwyer M.G., Dolezal O., Krasensky J., Bergsland N., et al. MRI results from a randomised, double-blind, placebo-controlled study of intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 12 Suppl 1 (2006) P701, S200
24. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 3 (1983) 227-231
25. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
26. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253 1 (2006) 98-108
27. Smith S.M., De Stefano N., Jenkinson M., and Matthews P.M. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25 3 (2001) 466-475
28. Smith S.M., Zhang Y., Jenkinson M., Chen J., Matthews P.M., Federico A., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 1 (2002) 479-489
29. Smith S.M. Fast robust automated brain extraction. Hum Brain Mapp 17 3 (2002) 143-155
30. Zhang Y., Brady M., and Smith S.M. Segmentation of brain MR images through a hidden Markov random field model and the expectation maximization algorithm. IEEE Trans Biomed Image 20 (2001) 45-57
31. Benedict R.H., Zivadinov R., Carone D.A., Weinstock-Guttman B., Gaines J., Maggiore C., et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol 26 7 (2005) 1824-1831
32. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 7 (2001) 1239-1247
33. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 Pt 11 (2005) 2705-2712
34. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68:S72-S82.
35. Ge Y., Grossman R.I., Babb J.S., Rabin M.L., Mannon L.J., and Kolson D.L. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol 23 8 (2002) 1327-1333
36. Sastre-Garriga J., Ingle G.T., Chard D.T., Cercignani M., Ramio-Torrenta L., Miller D.H., et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128 Pt 6 (2005) 1454-1460
37. Chen J.T., Narayanan S., Collins D.L., Smith S.M., Matthews P.M., and Arnold D.L. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 23 3 (2004) 1168-1175
38. Tedeschi G., Lavorgna L., Russo P., Prinster A., Dinacci D., Savettieri G., et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 65 2 (2005) 280-285
39. Rudick R.A., Fisher E., Lee J.C., Duda J.T., and Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 6 6 (2000) 365-372
40. Fisher E., Rudick R.A., Simon J.H., Cutter G., Baier M., Lee J.C., et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59 9 (2002) 1412-1420
41. Fisher E., Rudick R.A., Cutter G., Baier M., Miller D., Weinstock-Guttman B., et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6 6 (2000) 373-377
42. Rudick R.A., Lee J.C., Simon J., and Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 60 2 (2006) 236-242
43. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15 3 (2002) 239-245
44. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47 6 (2000) 707-717
45. Zivadinov R., and Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 14 3 Suppl (2004) 27S-35S
46. Zivadinov R., and Bakshi R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci 9 (2004) 665-683
47. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 5 4 (1999) 283-286
48. Dwyer M.G., Abdelrahman N., Weinstock-Guttman B., Srinivasaraghavan B., Prakash R., Hussein S., et al. Quantitative analysis of lesion load progression in advanced multiple sclerosis. Mult Scler 11 Suppl 1 (2005) 68, S14
49. Li D.K., Held U., Petkau J., Daumer M., Barkhof F., Fazekas F., et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66 9 (2006) 1384-1389
50. Cifelli A., Arridge M., Jezzard P., Esiri M.M., Palace J., and Matthews P.M. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52 5 (2002) 650-653
51. Vercellino M., Plano F., Votta B., Mutani R., Giordana M.T., and Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 64 12 (2005) 1101-1107
52. Confavreux C., and Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 108 3 (2006) 327-332
53. Lublin F.D., Baier M., and Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61 11 (2003) 1528-1532
54. Rudick R.A., Fisher E., Lee J.C., Simon J., and Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53 8 (1999) 1698-1704